New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - natalizumab 20 mg/ml;   - solution for infusion - 300 mg/15ml - active: natalizumab 20 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - indicated as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (ms) to delay the progression of physical disability and to reduce the frequency of relapse. the safety and efficacy of tysabri beyond two years are unknown

Kanada - Ingliż - Health Canada

celltrion healthcare co ltd - trastuzumab - kit - 440mg - trastuzumab 440mg - antineoplastic agents

Kanada - Ingliż - Health Canada

celltrion healthcare co ltd - trastuzumab - powder for solution - 150mg - trastuzumab 150mg - antineoplastic agents

Ġordan - Ingliż - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 100 mg - 100 mg

Ġordan - Ingliż - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 400 mg - 400 mg

Kanada - Ingliż - Health Canada

samsung bioepis co., ltd - trastuzumab - powder for solution - 150mg - trastuzumab 150mg

Kanada - Ingliż - Health Canada

samsung bioepis co., ltd - trastuzumab - powder for solution - 440mg - trastuzumab 440mg

Iżrael - Ingliż - Ministry of Health

amgen europe b.v. - sotorasib - film coated tablets - sotorasib 120 mg - sotorasib - lumykras is indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an approved test, who have received at least one prior systemic therapy.

Malta - Ingliż - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride -